What is Agios Pharmaceuticals's SG&A?

Agios Pharmaceuticals (AGIO) reported SG&A of $48.3M in Q1 2026.

How has Agios Pharmaceuticals's SG&A changed year-over-year?

Agios Pharmaceuticals's SG&A increased by 16.3% year-over-year, from $41.53M to $48.3M.

What is the long-term trend for Agios Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), Agios Pharmaceuticals's SG&A has grown at a 10.4% compound annual growth rate (CAGR), from $121.45M to $180.28M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Agios Pharmaceuticals AGIO SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

PfizerPFE

$2.96B-2.3%

Vertex PharmaceuticalsVRTX

$493.7M+24.5%

IncyteINCY

$328.09M+0.7%

BioMarin PharmaceuticalsBMRN

$258.29M+25.3%

Disc MedicineIRON

$23.62M+93.9%

Segments

By segment

See full

Reportable Segment$48.3M+16.3%

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's SG&A?: Agios Pharmaceuticals (AGIO) reported SG&A of $48.3M in Q1 2026.
How has Agios Pharmaceuticals's SG&A changed year-over-year?: Agios Pharmaceuticals's SG&A increased by 16.3% year-over-year, from $41.53M to $48.3M.
What is the long-term trend for Agios Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), Agios Pharmaceuticals's SG&A has grown at a 10.4% compound annual growth rate (CAGR), from $121.45M to $180.28M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.